立体定向体部放疗联合免疫检查点抑制剂治疗晚期或复发非小细胞肺癌的真实世界分析:单中心经验
本单中心回顾性研究纳入2017年1月至2021年12月接受SBRT同步ICI治疗的晚期或复发NSCLC患者144例,中位随访25.6个月。中位PFS为13.7个月,中位OS为52.8个月;疾病控制期SBRT组(78例)中位PFS 17.9个月、5年OS率61.2%,进展期 salvge 意向组(66例)中位PFS 8.0个月、中位OS 30.6个月。
要点
- 144例晚期或复发NSCLC患者接受SBRT同步ICI,中位PFS 13.7个月,中位OS 52.8个月。
- 疾病控制期SBRT组(78例)中位PFS 17.9个月,未达中位OS,5年OS率61.2%。
- 进展期SBRT组(66例)中位PFS 8.0个月,中位OS 30.6个月。
核心结论
- SBRT联合ICI在疾病控制状态下及以挽救意向针对进展病灶时,均显示出对晚期或复发NSCLC有利的生存。
- 作者认为需要未来前瞻性研究探讨最佳SBRT剂量方案和合适的联合策略以协同ICI。
研究设计与样本
- 单中心回顾性收集2017年1月至2021年12月在本机构接受SBRT同步ICI治疗的晚期或复发NSCLC患者。
- 共纳入144例患者,分为两组:第1组(n=78)在一线或后线ICI治疗期间初始或针对残留肿瘤行SBRT;第2组(n=66)无论一线或后线ICI治疗,针对进展肿瘤行SBRT。
主要发现
- 中位随访25.6个月(范围3.6至56.2个月),全组中位PFS为13.7个月(95%CI 10.4至17.1),中位OS为52.8个月(95%CI 30.6至未获得)。
- 第1组(n=78)中位PFS为17.9个月(95%CI 14.5至29.8),中位OS未达到,5年OS率为61.2%。
- 第2组(n=66)中位PFS为8.0个月(95%CI 6.0至13.1),中位OS为30.6个月(95%CI 21.5至未获得)。
局限性
- 原文报告为单中心回顾性研究。
- 原文结论指出需要未来前瞻性研究探讨最佳SBRT剂量方案和合适的联合策略以协同ICI。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to assess the value of stereotactic body radiotherapy (SBRT) delivered under the situation of controlled or progressed disease during ICI therapy in advanced or recurrent NSCLC. METHODS: We retrospectively collected patients with advanced or recurrent NSCLC who received SBRT concurrently with ICI in our institution between January 2017 and December 2021. Patients were divided into two groups, including those for whom SBRT was delivered initially or to the residual tumors during the first- or later-line ICI treatment (Group 1), and those for whom SBRT was given to the progressed tumors irrespective of first- or later-line ICI treatment (Group 2). RESULTS: A total of 144 patients were included. With median follow-up duration of 25.6 (range: 3.6 to 56.2) months, median progression-free survival (PFS) was 13.7 (95 % CI: 10.4 to 17.1) months and median overall survival (OS) was 52.8 [95 % CI: 30.6 to not available (NA)] months. In Group 1 (n = 78), median PFS was 17.9 (95 % CI: 14.5 to 29.8) months while median OS was not reached and 5-year OS rate was 61.2 %. In Group 2 (n = 66), median PFS was 8.0 (95 % CI: 6.0 to 13.1) months and median OS was 30.6 (95 % CI: 21.5 to NA) months. CONCLUSIONS: SBRT combined with ICI demonstrated favorable survival for advanced or recurrent NSCLC, delivered in a controlled-disease situation as well as to progressed diseases with salvage-intent. Future prospective studies are warranted to investigate the optimal SBRT dose regimen and appropriate combination strategy to synergize ICI.
引用
- Yao D, Zhu X, Guo J, et al. A real-world analysis of stereotactic body radiotherapy combined with immunotherapy in advanced or recurrent non-small cell lung cancer (NSCLC): A single-center experience. Clin Transl Radiat Oncol. 2024. PMID: 38770061. doi:10.1016/j.ctro.2024.100787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。